Sign In
Buy MDT
Medtronic Earnings Calls
| Release date | Jun 03, 2026 |
| EPS estimate | $1.54 |
| EPS actual | $1.55 |
| EPS Surprise | 0.649% |
| Revenue estimate | 9.62B |
| Revenue actual | 9.807B |
| Revenue Surprise | 1.94% |
| Release date | Feb 17, 2026 |
| EPS estimate | $1.34 |
| EPS actual | $1.36 |
| EPS Surprise | 1.49% |
| Revenue estimate | 8.911B |
| Revenue actual | 9.017B |
| Revenue Surprise | 1.19% |
| Release date | Nov 18, 2025 |
| EPS estimate | $1.31 |
| EPS actual | $1.36 |
| EPS Surprise | 3.82% |
| Revenue estimate | 8.867B |
| Revenue actual | 8.961B |
| Revenue Surprise | 1.06% |
| Release date | Aug 19, 2025 |
| EPS estimate | $1.23 |
| EPS actual | $1.26 |
| EPS Surprise | 2.44% |
| Revenue estimate | 8.379B |
| Revenue actual | 8.578B |
| Revenue Surprise | 2.38% |
Last 4 Quarters for Medtronic
Below you can see how MDT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 19, 2025 |
| Price on release | $89.90 |
| EPS estimate | $1.23 |
| EPS actual | $1.26 |
| EPS surprise | 2.44% |
| Date | Price |
|---|---|
| Aug 13, 2025 | $92.91 |
| Aug 14, 2025 | $91.98 |
| Aug 15, 2025 | $93.02 |
| Aug 18, 2025 | $92.81 |
| Aug 19, 2025 | $89.90 |
| Aug 20, 2025 | $93.22 |
| Aug 21, 2025 | $91.10 |
| Aug 22, 2025 | $92.71 |
| Aug 25, 2025 | $92.04 |
| 4 days before | -3.24% |
| 4 days after | 2.38% |
| On release day | 3.69% |
| Change in period | -0.94% |
| Release date | Nov 18, 2025 |
| Price on release | $100.80 |
| EPS estimate | $1.31 |
| EPS actual | $1.36 |
| EPS surprise | 3.82% |
| Date | Price |
|---|---|
| Nov 12, 2025 | $95.81 |
| Nov 13, 2025 | $96.14 |
| Nov 14, 2025 | $95.87 |
| Nov 17, 2025 | $96.28 |
| Nov 18, 2025 | $100.80 |
| Nov 19, 2025 | $100.34 |
| Nov 20, 2025 | $99.35 |
| Nov 21, 2025 | $101.20 |
| Nov 24, 2025 | $103.20 |
| 4 days before | 5.21% |
| 4 days after | 2.38% |
| On release day | -0.456% |
| Change in period | 7.71% |
| Release date | Feb 17, 2026 |
| Price on release | $96.41 |
| EPS estimate | $1.34 |
| EPS actual | $1.36 |
| EPS surprise | 1.49% |
| Date | Price |
|---|---|
| Feb 10, 2026 | $101.42 |
| Feb 11, 2026 | $101.08 |
| Feb 12, 2026 | $100.88 |
| Feb 13, 2026 | $99.49 |
| Feb 17, 2026 | $96.41 |
| Feb 18, 2026 | $98.49 |
| Feb 19, 2026 | $97.58 |
| Feb 20, 2026 | $96.86 |
| Feb 23, 2026 | $98.61 |
| 4 days before | -4.94% |
| 4 days after | 2.28% |
| On release day | 2.16% |
| Change in period | -2.77% |
| Release date | Jun 03, 2026 |
| Price on release | $77.95 |
| EPS estimate | $1.54 |
| EPS actual | $1.55 |
| EPS surprise | 0.649% |
| Date | Price |
|---|---|
| May 28, 2026 | $75.57 |
| May 29, 2026 | $73.81 |
| Jun 01, 2026 | $73.98 |
| Jun 02, 2026 | $73.75 |
| Jun 03, 2026 | $77.95 |
| Jun 04, 2026 | $81.93 |
| Jun 05, 2026 | $81.67 |
| Jun 08, 2026 | $80.69 |
| Jun 09, 2026 | $81.98 |
| 4 days before | 3.15% |
| 4 days after | 5.17% |
| On release day | 5.11% |
| Change in period | 8.48% |
Medtronic Earnings Call Transcript Summary of Q2 2026
Medtronic reported a strong fiscal Q2 (ended Oct 24, 2025) with revenue of $9.0B, organic revenue growth of 5.5% and adjusted EPS of $1.36 (up 8%). Management said momentum is accelerating across several enterprise growth drivers: pulsed field ablation (PFA) in cardiac ablation (71% growth; PFA is now ~75% of ablation revenue and the installed base of mapping systems doubled in the quarter), Simplicity renal denervation (RDN) for hypertension (recent favorable Medicare NCD and accelerating commercial payer wins), AltaViva tibial neuromodulation for urinary incontinence (early U.S. launch demand strong), HUGO robotics, and diabetes sensors/insulin delivery (new sensor launches and substantial pre-orders). Management raised FY26 revenue guidance to ~5.5% organic growth and increased EPS guidance to $5.62–$5.66, noting an FX tailwind and an anticipated tariff headwind (~$185M for FY26). They are deliberately increasing R&D and targeted SG&A investments to accelerate adoption of these growth drivers while maintaining discipline in G&A. The company reiterated a targeted path to ~10% R&D over time, plans for tuck-in M&A (focused on high-growth, near-market assets), and that the planned separation/IPO of the MiniMed diabetes business remains on track for completion by end of calendar 2026. Management expects further revenue acceleration in H2 FY26 and high-single-digit EPS growth in FY27 driven by stronger top-line momentum and improving mix.
